July 30, 2007
Sucampo Submits sNDA for Lubiprostone in the US: Takeda Takeda Pharmaceutical announced on July 13 that Sucampo Pharmaceuticals, Inc., has submitted a supplemental new drug application (sNDA) to the US FDA to seek market approval for a lower-strength lubiprostone 8...read more